Post

XY0206: A promising sunitinib-derived FLT3 Inhibitor targeting therapy-resistant acute myeloid leukemia: doi.org/10.1172/JCI2... Associate editor Yiping Yang discusses the clinical relevance for XY0206 in an Editor’s Note on Shen et al.: doi.org/10.1172/JCI2... @the-asci.org